BTX - BioTime, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.1700
+0.0200 (+1.74%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.1500
Open1.1500
Bid0.00 x 1800
Ask0.00 x 1400
Day's Range1.1400 - 1.1900
52 Week Range0.6600 - 2.9000
Volume650,309
Avg. Volume893,154
Market Cap148.799M
Beta (3Y Monthly)3.78
PE Ratio (TTM)N/A
EPS (TTM)-0.58
Earnings DateMar 13, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two affiliated companies, OncoCyte Corporation (OncoCyte) (NYSE American: OCX), and Asterias Biotherapeutics, Inc. (Asterias) (NYSE American: AST). “In the past five months, BioTime has made rapid progress toward its commitment to become a leading cell therapy company by focusing on clinical-stage cell therapy product candidates with promising human data and supporting their development in part through targeted transactions among its affiliated companies,” stated Brian M. Culley, Chief Executive Officer of BioTime, Inc.

  • ACCESSWIRE12 days ago

    Most Intriguing Companies on the New LD Micro Index

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Friday, LD Micro reinstituted their nearly 1000 company index of micro-caps, with the belief that our industry needs a truly accurate indicator of what is ...

  • GlobeNewswire18 days ago

    BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation (OncoCyte) (OCX), a developer of novel, non-invasive tests for the early detection of cancer, has reported positive results from an R&D validation study of DetermaVu™, a non-invasive, liquid biopsy test intended to facilitate clinical decision making in lung cancer diagnosis. As outlined in OncoCyte’s announcement, the R&D validation study demonstrated a sensitivity of 90% (95% CI 82%-95%) and specificity of 75% (95% CI 68%-81%) of DetermaVu™ on a prospectively collected cohort of 250 patient blood samples that were blinded to laboratory operators.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...

  • Business Wirelast month

    AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity

    ALAMEDA, Calif.-- -- 30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels found in young adults Loss of brown fat as a result of aging is associated with obesity ...

  • GlobeNewswirelast month

    BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD

    Traditionally, the sub-retinal space is accessed via vitrectomy (removal of the vitreous, the gel-like substance that fills the eye), followed by an injection into the eye and through the retina. Orbit Biomedical’s injection system is designed to precisely and consistently deliver therapeutics to the sub-retinal space via a suprachoroidal route, avoiding the need for a vitrectomy and perforation of the retina. “Orbit Biomedical’s specifically-designed device offers surgeons an innovative solution for the delivery of therapies to the sub-retinal space, a well-known challenge in ophthalmology,” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • GlobeNewswirelast month

    BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts, M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective January 7, 2019. "I’m excited to welcome Brandi to the BioTime team during this critical period in which we increase the focus on our clinical-stage product candidates and improve our business structure through recently-announced and pending transactions involving our affiliated companies, AgeX (NYSE American: AGE) and Asterias (NYSE American: AST),” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • Business Wire2 months ago

    BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor Conference on January 7th, 2019 at 9am Pacific Time at the Hilton San Francisco Union Square Hotel in the Franciscan A Ballroom in San Francisco, CA. “Our vision is to build BioTime into the premiere cell therapy company, pioneering whole-cell transplants to address unmet medical conditions such as macular degeneration and spinal cord injury1, which have not yielded to small molecule approaches,” stated Brian M. Culley, Chief Executive Officer of BioTime. “Awareness of our mission is vital and our presentation at Biotech Showcase is one of our first opportunities to share our updated plans with a broad audience and build support for BioTime’s short- and long-term objectives.

  • Business Wire2 months ago

    AgeX Therapeutics to Present at Biotech Showcase 2019

    AgeX Therapeutics, Inc. , a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase, to be held January 7-9, 2019 in San Francisco, California.

  • BioTime, Inc. (BTX): Are Hedge Funds Right About This Stock?
    Insider Monkey2 months ago

    BioTime, Inc. (BTX): Are Hedge Funds Right About This Stock?

    With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was BioTime, Inc. (NYSEAMEX:BTX). BioTime, Inc. (NYSEAMEX:BTX) investors should be aware […]

  • Business Wire2 months ago

    BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke

    BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the publication of positive preclinical results which demonstrate that targeted intracerebral delivery of brain-derived neurotrophic factor utilizing HyStem®, BioTime’s proprietary hydrogel delivery platform technology, may mitigate ischemic brain injury and restore functional benefits by reducing neuroinflammation. The article entitled, “Intracerebral Delivery of Brain-Derived Neurotrophic Factor Using HyStem®-C Hydrogel Implants Improves Functional Recovery and Reduces Neuroinflammation in a Rat Model of Ischemic Stroke,” was published in the International Journal of Molecular Sciences and is authored by clinicians at the Stanford University School of Medicine, Department of Neurosurgery.

  • Business Wire3 months ago

    AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference

    AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerative Medicine conference 2018 in Valencia, Spain on Monday December 3, 2018. In his address, Dr. West will provide an update on AgeX product development, and will for the first time present data on the potential use of its proprietary induced Tissue Regeneration (iTRTM) technology in cancer diagnosis and therapy as well as in inducing the destruction of aged cells (a process known as “senolysis”). A copy of Dr. West’s presentation will be available on AgeX’s website at www.agexinc.com.

  • Business Wire3 months ago

    BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018

    BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 at 8am Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

  • Business Wire3 months ago

    AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American

    On November 28, 2018, AgeX’s former parent company, BioTime, Inc. (NYSE American: BTX) distributed approximately 12.7 million shares of AgeX common stock to BioTime shareholders in the ratio of one share of AgeX common stock for every 10 BioTime common shares owned. There are approximately 35.8 million shares of AgeX common stock outstanding of which approximately 1.7 million are held by BioTime and 16.4 million are held by Juvenescence Limited, a life science and biotech company developing therapies to increase healthy human longevity.

  • Business Wire3 months ago

    BioTime Announces Distribution of AgeX Therapeutics Shares

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the registration statement on Form 10, including the information statement relating to the distribution that was previously prepared and filed by AgeX Therapeutics, Inc. (“AgeX”), was declared effective by the Securities and Exchange Commission (“SEC”) on November 27, 2018, and that BioTime will proceed with the distribution of approximately 12.7 million AgeX shares owned by BioTime on a pro rata basis, to eligible BioTime shareholders beginning at 5:00pm ET today. Eligible BioTime shareholders are entitled under the distribution to receive one share of AgeX common stock for every 10 shares of BioTime common stock held as of the record date of November 16, 2018.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of BTX earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 BioTime Inc Earnings Call

  • Simply Wall St.3 months ago

    What Kind Of Shareholder Owns Most BioTime Inc (NYSEMKT:BTX) Stock?

    A look at the shareholders of BioTime Inc (NYSEMKT:BTX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see Read More...

  • Associated Press3 months ago

    BioTime: 3Q Earnings Snapshot

    On a per-share basis, the Alameda, California-based company said it had net income of 53 cents. Losses, adjusted for non-recurring gains, were 7 cents per share. The biotechnology company posted revenue ...

  • Business Wire3 months ago

    BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company

    BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc. (“Asterias”) (NYSE American: AST), today announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Asterias that are not currently owned by BioTime. Asterias stockholders will receive 0.71 shares of BioTime common shares for every share of Asterias common stock and will own approximately 16.2% of the combined company.

  • Business Wire3 months ago

    BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update

    ALAMEDA, Calif.-- -- Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence Ltd. Positive OpRegen® Data Presented at 2018 American Academy of Ophthalmology Annual Meeting Date Set for Distribution of AgeX Therapeutics Shares to BioTime Stockholders BioTime, Inc. , a clinical-stage ...

  • Business Wire3 months ago

    BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call

    Call moved to 5:30 a.m. PT / 8:30 a.m. ET on November 8th, 2018

  • Business Wire3 months ago

    BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has received the second installment payment of $10.8 million pursuant to the previously-announced sale of shares of AgeX Therapeutics Inc. (“AgeX”) to Juvenescence Limited (“Juvenescence”), a global leader in therapeutics focused on improving and extending human lifespans.